Date | Interest Coverage Ratio | Debt to Equity Ratio | Interest Expense To Sales | Inventory Turnover Ratio |
---|
CEO | Mr. Wang Chao |
IPO Date | April 15, 2011 |
Location | China |
Headquarters | No. 36, Jinghai Er Road |
Employees | 555 |
Sector | Health Care |
Industries |
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases. The company has a strategic collaboration with Pivotal S.L. to assess BDB-001, a monoclonal anti-C5a antibody, in a clinical trial in Europe in progressive severe COVID-19 patients caused by SARS-CoV-2. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.
Past 5 years
StockViz Staff
January 16, 2025
Any question? Send us an email